Are existing vaccines still effective against Opmiquerong? WHO and the European Drug Administration have made this judgment

According to Xinhua News Agency, the World Health Organization issued a statement on the 11th that the new crown vaccine that has been urgently used by the WHO is still effective against the Aomi Kerong strain, but the existing new crown vaccine may also need to be updated to continue to provide sufficient protection for people to deal with the current and future mutation of the new crown virus.

Experts from who's Technical Advisory Group on the Composition of COVID-19 Vaccines are currently analysing evidence related to "needing attention" variants and may revise recommendations for the components of THE NEW CORONAVIRUS vaccine lines accordingly, the statement said. According to the spread and pathogenicity of the mutated new coronavirus, WHO lists the mutated virus as "needing attention" or "needing attention", of which Omi kerong, Delta, etc. are all "need to pay attention" to the mutant strains.

The WHO Technical Advisory Group on the Composition of COVID-19 Vaccines was established last September and is composed of 18 experts from different disciplines. The expert group issued a temporary statement on the 11th, saying that the new crown vaccine that has been certified by the WHO emergency use is still effective against the mutant strains that "need attention" such as Omicron, especially for the severe illness and death of the new crown. But at the same time, experts also stressed the need to develop vaccines that can better prevent the infection and spread of the new crown virus in the future.

In addition, as the coronavirus mutates, the composition of existing COVID-19 vaccines may also need to be updated to ensure that the level of protection recommended by WHO continues to be provided in the face of infections and diseases caused by the Omiljun strain and other "concern-needing" variants that may arise in the future.

Specifically, the composition of the updated vaccine strain needs to be genetically similar to that of the ongoing mutant virus in terms of genes and antigens, be more effective at preventing infection, and be able to elicit a "broad, intense and long-lasting" immune response to "reduce the need for continuous booster needles."

WHO has also proposed options for updated protocols, including the development of monovalent vaccines for major circulating variants, polyvalent vaccines containing antigens from multiple "concerned" variants, or long-term vaccines with better ongoing development that are still effective against different variants.

In response to the current multi-country epidemic of the Olmikron strain, the expert group called for a wider global roll-out of full vaccination and enhanced vaccination programmes, hoping to help reduce the emergence of new "attention-needing" variants and reduce their harm.

━━━━━

European Drug Administration:

Omiqueron is less dangerous than Delta, and vaccines are still effective in preventing severe disease

The European Medicines Agency said on the 11th that according to the data obtained so far, the risk of the Olmiqueron strain is only between one-third and half of the Delta strain, and the new crown vaccine is still effective in preventing severe illness and hospitalization caused by infection with the Olmiqueron strain.

The European Drug Administration said in a statement released on the same day that while The Omilton appears to be more contagious than other mutant strains, studies from South Africa, the United Kingdom and some EU countries have shown a lower risk of hospitalization after contracting the Omiljun strain. Based on these studies, the agency estimates that the risk of the Olmiqueron strain is only between one-third and half that of delta strains.

The statement also said that some recently published studies have shown that the COVID-19 vaccine is less effective at preventing symptomatic infections caused by the Olmiqueron strain than other strains, and that this effectiveness has gradually diminished over time. As a result, more people who have already been vaccinated against COVID-19 may become infected with the Olmikron strain.

But these findings also suggest that the COVID-19 vaccine remains effective in preventing severe illness and hospitalization from infection with the Omiljun strain. The latest evidence, including real-world effectiveness data, also suggests that people who receive the vaccine booster are better protected.

The European Drug Administration said in a statement that efforts should continue to increase vaccination rates and accelerate the promotion of enhanced needle vaccination.

Edited by Sun Linzhi Chen Yuanyuan Source Xinhua News Agency

Duty Editor Gully